

Gerakas, April 30, 2026

FINANCIAL RESULTS ANNOUNCEMENT

The Company is headquartered in Gerakas, Attica.

The Group operates in the sectors of medical consumables and diagnostic centers.

The Group's sales, after rebates and clawback deductions, amounted to €17,954 thousand compared to €18,375 thousand in the corresponding period last year, representing a decrease of €421 thousand or 2.29%.

The Group's EBITDA increased by 10.64% and amounted to €3,773 thousand compared to €3,410 thousand in 2024.

Profit after tax increased by 32.60% and amounted to €1,769 thousand compared to €1,334 thousand in 2024.

The improvement in the above figures is primarily attributable to the performance of the Group's subsidiaries (diagnostic laboratories), driven by both the increase in their turnover and the reduction in the clawback rate.

Equity increased to €19,764 thousand from €18,569 thousand. The Group's solvency ratio (equity as a percentage of total assets excluding cash and cash equivalents and term deposits) stood at 89.80% as of December 31, 2025.

The Group's borrowings amount to €8,214 thousand and relate exclusively to the parent company. With regard to the financial figures of the parent company, "MEDICON HELLAS S.A.", turnover amounted to €16,465 thousand compared to €16,962 thousand in the corresponding period last year, marking a decrease of 2.93%.

The Company's EBITDA amounted to €3,320 thousand compared to €3,641 thousand in 2024, showing a decrease of 8.82%.

Profit after tax amounted to €1,552 thousand compared to €1,792 thousand in 2024.

The decline in the parent company's figures is attributable to the decrease in turnover and the increase in operating and financial expenses compared to the corresponding previous period.

Furthermore, the decrease was also affected by the first-time implementation of Article 72 of Law 5129/2024, concerning the imposition and settlement of rebates on medical technology products and reagent products.

Condensed Consolidated Statement of Profit or Loss (in € thousand)		
	2025	2024
Total Sales	17.954	18.375
Gross Profit	13.114	13.039
Other Operating Income	324	172
Administrative, R&D and Selling Expenses	-10.930	-11.380
Other Expenses & Losses	-249	-171
Profit before Tax & Investment Results	2.259	1.660
Financial Income/(Expenses)	-188	-110
Depreciation included in Operating Profit	1.514	1.749
Profit before Tax	2.071	1.550
Income Tax	-303	-216
Profit/(Loss) after Tax	1.769	1.334
Earnings per Share	0,3920	0,3091
Condensed Consolidated Statement of Financial Position (in € thousand)		
	2025	2024
ASSETS		
Non-Current Assets		
Owner-occupied Tangible Fixed Assets	7.293	6.996
Intangible Assets	38	48
Deferred Tax Assets	2.642	2.715
Other Long-term Receivables	30	32
Current Assets		
Inventories	3.512	2.862
Trade Receivables	7.251	8.612
Other Short-term Receivables	1.243	1.705
Other Current Assets	4.000	0
Cash and Cash Equivalents	6.678	8.514
TOTAL ASSETS	32.687	31.484
EQUITY & LIABILITIES		
Equity	19.764	18.569
Long-term Bank Borrowings	7.450	7.794
Other Long-term Liabilities	1.098	1.171
Short-term Bank Borrowings	763	612
Trade and Other Payables	3.612	3.338
TOTAL EQUITY & LIABILITIES	32.687	31.484